ОбзорГрафикНовостиTraderScreen

Morgan Stanley Put 500 LONN 20.12.../  DE000MG2EY35  /

Stuttgart
08.11.2024  13:19:48 Изменение-0.014 Бид22:00:39 Предложение22:00:39 Базовый актив Цена исполнения Дата истечения Тип опциона
0.070EUR -16.67% -
Величина цены спроса: -		 -
Величина цены предложения: -		 LONZA N 500.00 CHF 20.12.2024 Put
GlobeNewswire 26.08 Simtra BioPharma Solutions Appoints Dr. Lidia Serina as Head of Development Sciences
GlobeNewswire 23.08 Galapagos announces FDA clearance of IND application for Phase 1/2 ATALANTA-1 study of CD19 CAR-T, G...
GlobeNewswire 08.08 Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 06.08 Vaxcyte Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 14.06 Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at...
GlobeNewswire 13.06 Repligen Announces CEO Transition Plan
GlobeNewswire 30.05 Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively licens...
GlobeNewswire 15.05 Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ dec...
GlobeNewswire 08.05 Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire 08.05 Maravai LifeSciences Reports First Quarter 2024 Financial Results
GlobeNewswire 04.04 Galapagos showcases innovative approach in hematological cancer care with clinical and translational...
GlobeNewswire 04.04 Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’...
GlobeNewswire 27.02 Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire 15.02 Galapagos presents at EBMT-EHA annual meeting 2024
GlobeNewswire 04.01 Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further exp...
GlobeNewswire 19.12.2023 Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufacture...
GlobeNewswire 09.12.2023 Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 an...
GlobeNewswire 07.12.2023 Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at A...
GlobeNewswire 07.12.2023 Business Update
GlobeNewswire 06.11.2023 Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire 01.11.2023 Dr. Hartmut Tintrup joins Cellbox Solutions GmbH as new CEO
GlobeNewswire 19.10.2023 Viralgen welcomes back Andy Holt as CCO
GlobeNewswire 16.10.2023 Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumoc...
GlobeNewswire 02.10.2023 Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
GlobeNewswire 20.09.2023 Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023